BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Thyrocare brings blood based cancer screening profile

24 February 2020 | News

The Circulating Tumor Cell Cluster Detection Technology is clinically proven with a sensitivity of 90%, specificity of 97% and overall accuracy of 94%.



Thyrocare, a leading provider of wellness tests, has announced the launch of Cancer Screening Profile. This consists of ‘**Easycheck360™**’, a cancer screening test for the early detection of 16 types of cancers that is processed by **Datar Cancer Genetics** (Datar), and Thyrocare’s popular wellness profile ‘Aarogyam’, which is available for Rs. 8999.

Cancer screening through blood is a breakthrough, patented and pioneering test by Datar which is clinically proven in the world’s largest study with over 44,000 patients. The research data has been published and acknowledged by the International Journal of Cancer and other leading cancer journals.

Datar’s cancer detection technology is based on the discovery of the new systemic hallmark of cancer i.e. Circulating Tumor Cells and their clusters (C-ETACs) which are extensively present in cancer patients much before any clinical evidence can manifest and virtually undetectable in asymptomatic individuals. Two clinical trials registered in India have shown a sensitivity of 90%, specificity of 97% and overall accuracy of 94% to detect C-ETACs. The test requires just 10 ML of blood and the results are provided within 10 days.

Thyrocare’s Aarogyam is an array of well accepted, cost effective wellness packages. It offers high quality investigations for many metabolic disorders, which have evolved over the last 20 years with a collective experience of testing 15 crore customers and 750 crore investigations. Thyrocare services and networks are present in 3000 locations across 10 countries.

Dr. Velumani, CEO of Thyrocare, said, “Cancer, the growing and most devastating disease, has no reliable screening tests for early diagnosis so far. Easycheck360™ launched by Datar Cancer Genetics has the potential to fill in the void and can impact early cancer diagnosis immensely. Cancer Screening Profile is a logical combination of Easycheck360™ and Aarogyam that anybody over 35 years should consider annually.”

Mr. Rajan Datar, Managing Director of Datar Cancer Genetics, said, “Easycheck360™ is a breakthrough test for the detection of most solid organ cancers such as breast, ovary, lung, colon and liver cancers. Our technology is very sensitive and specific to detect Circulating Tumor Cell clusters in the blood, which is by far the most powerful evidence of malignant activity in the body.”